PUMA BIOTECHNOLOGY, INC.
About PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $228.4M
- Net income
- $31.1M
- Total assets
- $216.3M
- Market cap
- $357.8M
- Gross margin
- 74.5%
- Operating margin
- 16.3%
- Net margin
- 13.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $228.4M
- Cost of revenue
- $58.2M
- Gross profit
- $170.2M
- Operating expenses
- $132.9M
- Operating income
- $37.3M
- Income tax
- $4.7M
- Net income
- $31.1M
- EPS (basic)
- $0.62
- EPS (diluted)
- $0.61
Balance sheet
- Total assets
- $216.3M
- Current assets
- $162.7M
- Total liabilities
- $86.0M
- Current liabilities
- $81.3M
- Shareholders’ equity
- $130.3M
Cash flow
- Operating cash flow
- $41.8M
- Investing cash flow
- -$36.2M
- Financing cash flow
- -$45.2M
- Net cash flow
- -$39.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $357.8M
- P/E ratio
- 11.2
- EPS (diluted)
- $0.61
- Shares outstanding
- 52.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 21, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $31.1M in FY2025.
- Revenue grew 1% from FY2020 to FY2025.
- Gross margin of 74.5%, net margin 13.6%.
- Trading 12% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 11.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review PUMA BIOTECHNOLOGY, INC..
Write a review
News about PUMA BIOTECHNOLOGY, INC.
News & sentiment via Polygon.io
